Cameron Santoro

3 weeks ago | ajmc.com | Cameron Santoro

Despite being a high-income country, the US has the highest and an increasing maternal mortality rate, primarily due to underfunded and misdirected research that often prioritizes fetal development over the pregnant person's health, exacerbated by restrictive policies and a lack of involvement from frontline women's health specialists in setting research priorities, according to a review published online today in JAMA Health Forum.1 Recent efforts to prioritize women's health research, like...

3 weeks ago | centerforbiosimilars.com | Cameron Santoro

June 6, 2025Here are the top 5 biosimilar articles for the week of June 2, 2025. Number 5: FDA approvals for new biosimilars like Starjemza and Hadlima enhance treatment options, addressing urgent needs for affordability and policy reform. Number 4: Denosumab biosimilars Wyost and Jubbonti launch in the US, enhancing access to affordable treatments for osteoporosis and cancer-related skeletal events.

3 weeks ago | ajmc.com | Cameron Santoro

The total economic burden of Alzheimer disease and related dementias (ADRD) is expected to be disproportionately high for minoritized groups, particularly that from unpaid caregiving, highlighting the need for policies to mitigate these economic strains for all US residents, according to a study published in JAMA Network Open.1 Alzheimer disease is the most common form of dementia and contributes to 60% to 70% of cases among US residents 65 years and older.2 Related dementias include vascular...

3 weeks ago | centerforbiosimilars.com | Cameron Santoro

Infliximab biosimilars (infliximab-abda and infliximab-dyyb) may delay treatment after patients switch from the reference product, suggesting a possible risk factor for flaring/loss of disease control, according to a study published in the Journal of Pharmacy Technology.1Clinicians often treat rheumatic diseases like ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and uveitis, with the anti-tumor necrosis factor agent, infliximab.

3 weeks ago | ajmc.com | Cameron Santoro

Utilizing LGBTQ+-inclusive language in dermatology can lead to more accurate patient data and stronger patient-clinician relationships while addressing existing health care barriers and improving outcomes, according to a research letter published in JAMA Dermatology.1 Individuals who identify as LGBTQ+ often experience barriers to health care, and the community faces substantial mistreatment in medicine.2 Previous research has found LGBTQ+ communities lack access to health care due to...